

# Association Between Serum 5-methyltetrahydrofolate and Homocysteine in Chinese Hypertensive Participants With Different MTHFR C677T Polymorphisms: A Cross-sectional Study

**Yu Cheng**

China Pharmaceutical University

**Shuai Liu**

China Pharmaceutical University

**Duo Chen**

China Pharmaceutical University

**Yiman Yang**

China Pharmaceutical University

**Qiongyue Liang**

China Pharmaceutical University

**Ya Huo**

China Pharmaceutical University

**Ziyi Zhou**

China Agricultural University

**Nan Zhang**

Peking University First Hospital

**Zhuo Wang**

China Agricultural University

**Lishun Liu**

China Agricultural University

**Yun Song**

China Agricultural University

**Xiangyi Liu**

Beijing Tongren Hospital

**Yong Duan**

Kunming Medical University First Affiliated Hospital

**Xiuwen Liang**

China Mongolia Hospital of Hulunbuir

**Bingjie Hou**

The Fourth Central Hospital of Baoding City

**Binyan Wang**

Anhui Medical University

**Genfu Tang**

Anhui Medical University

**Xianhui Qin**

Southern Medical University Nanfang Hospital

**Fangrong Yan** (✉ [f.r.yan@outlook.com](mailto:f.r.yan@outlook.com))

China Pharmaceutical University College of Life Science and Technology

---

## Research

**Keywords:** 5-methyltetrahydrofolate, homocysteine, MTHFR C677T

**Posted Date:** November 15th, 2021

**DOI:** <https://doi.org/10.21203/rs.3.rs-1057953/v1>

**License:** © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

---

# Abstract

**Background and aims:** Clarifying the association between 5-methyltetrahydrofolate and homocysteine and the effect pattern of methylene tetrahydrofolate reductase (MTHFR C677T) may contribute to the management of homocysteine and may serve as a significant reference for a randomized controlled trial of 5-methyltetrahydrofolate intervention. This study aimed to reveal the association between these two biochemical indices.

**Methods:** Study population was drawn from the baseline data of the China Stroke Primary Prevention Trial (CSPPT), including 2,328 hypertensive participants. 5-methyltetrahydrofolate and homocysteine were determined by stable-isotope dilution liquid chromatography-tandem mass spectrometry and automatic clinical analyzers, respectively. MTHFR C677T polymorphisms were detected using TaqMan assay. Multiple linear regression was performed to evaluate the association between serum 5-methyltetrahydrofolate and homocysteine.

**Results:** There was a significant inverse association between 5-methyltetrahydrofolate and homocysteine when 5-methyltetrahydrofolate was  $\geq 10$  ng/mL, and this association was modified by MTHFR C677T (per 1-ng/mL increment; All:  $a = -0.50$ ,  $P < 0.001$ ; CC:  $c = -0.14$ ,  $P = 0.087$ ; CT:  $k = -0.20$ ,  $P = 0.011$ ; TT:  $g = -1.19$ ,  $P < 0.001$ ). Moreover, the decline in trend in genotype TT participants was stronger than in genotype CC participants ( $P$  for difference  $< 0.001$ ) and genotype CT participants ( $P$  for difference  $< 0.001$ ), while there was no significant difference between genotype CC and genotype CT participants ( $P$  for difference = 0.757).

**Conclusions:** Our data showed a non-linear association between serum homocysteine and 5-methyltetrahydrofolate among Chinese hypertensive adults, however, it could be inversely linearly fitted when serum 5-methyltetrahydrofolate was  $\geq 10$  ng/mL, and this association was modified by MTHFR C677T.

## 1. Introduction

Homocysteine (Hcy), a sulfur-containing amino acid, is an intermediate product in the normal metabolism from methionine to cysteine. It has been shown that hyperhomocysteinemia (blood concentration of Hcy  $> 15 \mu\text{mol/L}$ ) is significantly correlated with cardiovascular disease[1–3]. Evidence from the CSPPT (China Stroke Primary Prevention Trial) showed that appropriate supplementation of folic acid can significantly reduce Hcy concentrations, thereby reducing the risk of stroke and delaying the progression of chronic kidney disease (CKD) among patients with mild-to-moderate CKD[4].

Although numerous randomized controlled trials investigated the efficacy of lowering Hcy with folic acid for cardiovascular disease, a level above a certain threshold dose results in accumulation of unmetabolized folate[5, 6], which could affect the normal homeostatic regulation of folate and has been reported to be associated with reduced natural killer cell cytotoxicity[7]. 5-methyltetrahydrofolate (5-MeTHF), the major bioactive form of folate metabolism, might be a potential alternative to folic acid

because of its advantages: it does not require an activation process, avoids the influence of low enzymatic activity or genetic defects, and is free of the possible accumulation of unmetabolised folate.

In terms of chemical mechanism, methylenetetrahydrofolate reductase (MTHFR) is a crucial enzyme in folic acid metabolism[8]. A common mutation in the gene encoding the MTHFR enzyme is a C to T substitution at bp 677 (MTHFR C677T). The thermolabile mutated phenotype (TT) has a residual activity of about 50% of that of the wild-type controls (CC), resulting in elevated levels of Hcy[9].

Studies have demonstrated significantly negative associations between 5-MeTHF and Hcy among different populations [10–12]. However, these studies were not designed to investigate these associations directly, and the levels of evidence from these studies are limited by intervention time, sample size, and participant characteristics. Moreover, the influence of MTHFR C677T on the relationship between 5-MeTHF and Hcy is overlooked in the majority of the current studies. It is estimated that 26% of the world's population suffers from hypertension and this is expected to increase to 29% by 2025[13]. Therefore, it is of high practical significance to evaluate the relationship between 5-MeTHF and Hcy in hypertensive populations.

Overall, clarifying the association between 5-MeTHF and Hcy and the effect pattern of MTHFR C677T may contribute to the management of Hcy and may serve as a significant reference for a randomized controlled trial of 5-MeTHF intervention. We conducted a cross-sectional study (a sub-study of the CSPPT) in a Chinese rural population with hypertension to reveal the relationship between 5-MeTHF and Hcy and to evaluate the effect pattern of the MTHFR C677T polymorphism.

## 2. Methods

### 2.1 Data Availability Statement

The parent study (the China Stroke Primary Prevention Trial, CSPPT) was approved by the Ethics Committee of the Institute of Biomedicine, Anhui Medical University, Hefei, China (federal-wide assurance number: FWA00001263). All participants provided written, informed consent. The data, analytic methods and study materials that support the findings of this study will be available from the corresponding author on request after the request is submitted and formally reviewed and approved by the Ethics Committee of the Institute of Biomedicine, Anhui Medical University.

### 2.2 Study population and design (Parent design, CSPPT)

The methods and major results of the CSPPT have been reported elsewhere[14]. Briefly, the CSPPT was a multi-community, randomized, double-blinded, controlled trial conducted from 19 May 2008 to 24 August 2013 in 32 communities in China. Eligible participants were men and women aged 45-75 y with hypertension, defined as seated, resting systolic blood pressure (SBP)  $\geq$  140 mmHg or/and diastolic blood pressure (DBP)  $\geq$  90 mmHg at both the screening and recruitment visit, or who were taking any antihypertensive medication. The major exclusion criteria included a history of physician-diagnosed

stroke, myocardial infarction, heart failure, postcoronary revascularization, or congenital heart disease. A total of 20,702 eligible participants, stratified by the methylenetetrahydrofolate reductase (MTHFR) C677T genotype (CC, CT or TT), were randomly assigned in a 1:1 ratio to 1 of 2 treatment groups: a daily oral dose of 1 tablet containing 10 mg enalapril and 0.8 mg folic acid (the enalapril + folic acid group) or a daily oral dose of 1 tablet containing 10 mg enalapril only (the enalapril group). Participants were engaged in follow-up every 3 months.

## 2.3 Cross-sectional study (Sub study)

Using data from the CSPPT, we established a sub-database of 2,590 participants, including all the 1,326 incident stroke, cancer, or all-cause mortality cases at the exit site visit matched with 1,264 corresponding controls. Controls were randomly chosen from the baseline CSPPT participants who did not develop the corresponding end points during the follow-up, and were matched with the cases on a 1:1 ratio for age ( $\pm$  1 year), sex, treatment group and study site. Our final analysis included 2,328 participants, after excluding 187 participants without baseline serum, 47 participants with missing data of 5-MeTHF or/and Hcy, and 24 participants with extreme value of 5-MeTHF (**Supplemental Figure 1**).

## 2.4 Laboratory assays

Serum 5-methyltetrahydrofolate concentration was measured by stable-isotope dilution liquid chromatography-tandem mass spectrometry using 4500MD (AD SCIEX) in a commercial lab (Shenzhen Tailored Medical Laboratory, China). Serum folate, vitamin B12 and vitamin D3 were measured by a commercial laboratory with the use of a chemiluminescent immunoassay (New Industrial). Serum homocysteine, fasting lipids, and glucose levels were measured using automatic clinical analyzers (Beckman Coulter) at the core laboratory of the National Clinical Research Center for Kidney Disease, Nanfang Hospital, Guangzhou, China. MTHFR C677T (rs1801133) polymorphisms were detected on an ABI Prism 7900HT sequence detection system (Life Technologies) using the TaqMan assay.

## 2.5 Statistical analysis

Baseline characteristics were presented as median (interquartile range, IQR) for continuous variables and as  $n$  (%) for categorical variables. Differences in baseline characteristics between different genotypes were compared through the use of a Kruskal test for continuous variables and a chi-square test for categorical variables.  $\beta$ s of Hcy concentration in relation to serum 5-MeTHF concentration were calculated through the use of multiple linear regression models, with adjustment for sex, age, study site, body mass index (BMI), systolic blood pressure (SBP), diastolic blood pressure (DBP), estimated glomerular filtration rate (eGFR), total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), vitamin B12, vitamin D3, fasting glucose, folate, smoking (never, ever, and current), alcohol drinking (never, ever, and current) and MTHFR C677T polymorphisms (CC, CT, and TT) at baseline.

A 2-tailed  $P < 0.05$  was considered to be statistically significant in all analyses. R software (version 3.6.0) was used for all statistical analyses.

## 3. Results

### 3.1 Study participants and baseline characteristics

As shown in the flow chart (**Supplemental Figure 1**), 2,328 participants were included in the final analysis of this study. Baseline characteristics of study participants stratified by MTHFR C677T are shown in Table 1. Genotype CT participants and genotype TT participants had higher levels of Hcy concentrations, DBP, BMI, TC and fasting glucose but lower levels of 5-MeTHF concentrations, vitamin B12 and folate compared with genotype CC participants at baseline. Similar trends were found in males and females (**Supplemental Table 1, Supplemental Table 2**).

Table 1  
Baseline characteristics of the study participants stratified by MTHFR C677T

Characteristics	Total (N = 2328)	MTHFR C677T			P Value
		CC (N = 691)	CT (N = 1129)	TT (N = 580)	
Age, years	63.2 (57.5, 69.1)	64.3 (57.5, 70.1)	62.8 (57.5, 68.8)	63.4 (57.6, 68.3)	0.060
Male, n (%)	1127 (48.3)	290 (46.8)	561 (49.7)	275 (47.2)	0.437
BMI, kg/m <sup>2</sup>	24.2 (21.8, 26.9)	23.7 (21.2, 26.6)	24.3 (22.0, 27.0)	24.5 (21.9, 27.3)	0.002
SBP, mmHg	166.7 (156.0, 180.7)	166.0 (156.7, 180.0)	167.3 (155.3, 181.3)	167.3 (156.0, 180.8)	0.976
DBP, mmHg	93.3 (86.0, 100.7)	90.7 (83.3, 100.0)	94.0 (86.0, 100.7)	94.7 (87.3, 100.7)	< 0.001
eGFR, mL/min/1.73m <sup>2</sup>	92.2 (83.5, 99.1)	91.7 (81.7, 99.0)	92.7 (84.2, 99.0)	92.0 (83.9, 99.5)	0.286
TC, mmol/L	5.4 (4.7, 6.2)	5.3 (4.6, 6.1)	5.4 (4.7, 6.2)	5.5 (4.8, 6.3)	0.011
TG, mmol/L	1.4 (1.0, 1.9)	1.3 (1.0, 1.9)	1.4 (1.0, 1.9)	1.3 (1.0, 1.9)	0.754
HDL-C, mmol/L	1.3 (1.1, 1.6)	1.3 (1.1, 1.6)	1.3 (1.1, 1.6)	1.3 (1.1, 1.5)	0.987
Vitamin B12, pg/mL	382.9 (318.2, 478.5)	391.2 (323.6, 485.2)	388.0 (323.2, 485.2)	367.6 (307.7, 453.3)	0.001
Vitamin D3, ng/mL	19.1 (13.7, 25.3)	19.1 (14.3, 25.1)	19.2 (13.6, 25.1)	18.8 (13.5, 24.7)	0.145
Glu, mmol/L	5.4 (4.9, 6.1)	5.4 (4.9, 6.2)	5.4 (4.9, 6.2)	5.4 (5.0, 6.2)	0.001
Folate, ng/mL	7.8 (5.3, 10.4)	9.0 (6.2, 11.3)	8.0 (5.5, 10.4)	6.2 (4.6, 9.0)	< 0.001
5-MeTHF, ng/mL	5.4 (3.1, 9.0)	5.5 (3.1, 9.0)	5.6 (3.2, 9.5)	4.8 (2.8, 8.2)	0.002
Hcy, μmol/L	13.4 (11.1, 16.8)	12.6 (10.6, 15.2)	13.0 (11.0, 15.5)	16.4 (12.8, 24.9)	< 0.001

Values are median (interquartile range) or n (%). Differences in baseline characteristics were compared using chi-square test for categorical variables and Kruskal test for continuous variables. BMI, body-mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; TG, triglycerides; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; Glu, glucose; 5-MeTHF, 5-methyltetrahydrofolate; Hcy, homocysteine

### 3.2 Association of serum 5-MeTHF and Hcy and stratification by MTHFR C677T

Overall, there existed an apparent inverse association between serum 5-MeTHF and Hcy during the baseline period, no matter among all participants (Figure 1A) or stratified by MTHFR C677T (Figure 1B; solid, dotted and two-dash lines represent for genotype CC, CT and TT, respectively), but the association plateaued when the 5-MeTHF concentration was over 10 ng/mL (Supplemental Table 3). Thus, the 2,328 participants were divided into two subsets, one of which had concentrations of 5-MeTHF  $\leq$  10 ng/mL, while the other subset had concentrations over 10 ng/mL. Multiple linear regression was performed on both subsets (Supplemental Table 4). The results of the former subset were displayed in Table 2.



Table 2

Multiple linear regression model of Hcy on level of 5-MeTHF in all participants and stratified by MTHFR C677T genotype (5-MeTHF  $\leq$  10 ng/mL only)

5-MeTHF (ng/mL)	N	Hcy	Adjusted model	
		Median (IQR)	$\beta$ (95% CI)	P Value
<b>All Participants</b>				
Continuous	1840	13.8 (11.4, 17.5)	-0.50 (-0.69, -0.31)	< 0.001
Quartiles				
Q1 (< 2.7)	460	15.3 (12.7, 20.1)	<i>Ref</i>	
Q2 (2.7 - < 4.4)	460	14.6 (11.7, 18.1)	-2.18 (-3.32, -1.03)	< 0.001
Q3 (4.4 - < 6.4)	459	13.3 (11.3, 16.7)	-2.51 (-3.71, -1.31)	< 0.001
Q4 ( $\geq$ 6.4)	461	12.5 (10.5, 15.2)	-3.62 (-4.87, -2.38)	< 0.001
<i>P</i> for trend				< 0.001
<b>Genotype CC</b>				
Continuous	485	12.9 (10.8, 15.4)	-0.14 (-0.30, 0.02)	0.087
Quartiles				
Q1 (< 2.8)	121	14.0 (11.4, 16.2)	<i>Ref</i>	
Q2 (2.8 - < 4.5)	121	12.9 (11.1, 15.5)	-0.22 (-1.20, 0.76)	0.662
Q3 (4.5 - < 6.5)	121	12.3 (10.5, 14.7)	-0.47 (-1.48, 0.53)	0.353
Q4 ( $\geq$ 6.5)	122	12.5 (10.3, 14.6)	-0.98 (-2.04, 0.08)	0.070
<i>P</i> for trend				0.061
<b>Genotype CT</b>				
Continuous	869	13.3 (11.2, 16.5)	-0.20 (-0.35, -0.05)	0.011
Quartiles				
Q1 (< 2.7)	217	14.7 (12.5, 18.1)	<i>Ref</i>	
Q2 (2.7 - < 4.5)	217	14.1 (11.5, 16.9)	-0.64 (-1.54, 0.27)	0.170
Q3 (4.5 - < 6.5)	217	12.9 (11.2, 15.3)	-0.79 (-1.73, 0.16)	0.105
Q4 ( $\geq$ 6.5)	218	12.0 (10.1, 14.5)	-1.30 (-2.29, -0.30)	0.011

Adjusted for sex, age, study site, BMI, systolic blood pressure, diastolic blood pressure, estimated glomerular filtration rate, total cholesterol, triglycerides, high-density lipoprotein cholesterol, vitamin B12, vitamin D3, fasting glucose, folate, smoking and drinking at baseline.

5-MeTHF (ng/mL)	N	Hcy	Adjusted model	
		Median (IQR)	$\beta$ (95% CI)	P Value
<i>P</i> for trend				0.013
<b>Genotype TT</b>				
Continuous	486	17.3 (13.3, 26.1)	-1.19 (-1.77, -0.62)	< 0.001
Quartiles				
Q1 (< 2.7)	122	21.0 (15.8, 35.7)	<i>Ref</i>	
Q2 (2.7 - < 4.1)	121	17.9 (14.3, 27.4)	-5.92 (-9.46, -2.38)	0.001
Q3 (4.1 - < 6.2)	121	17.1 (13.2, 24.5)	-7.52 (-11.22, -3.81)	< 0.001
Q4 ( $\geq$ 6.2)	122	14.1 (11.7, 19.1)	-9.02 (-12.84, -5.20)	< 0.001
<i>P</i> for trend				< 0.001
Adjusted for sex, age, study site, BMI, systolic blood pressure, diastolic blood pressure, estimated glomerular filtration rate, total cholesterol, triglycerides, high-density lipoprotein cholesterol, vitamin B12, vitamin D3, fasting glucose, folate, smoking and drinking at baseline.				

A 1-ng/mL increment in 5-MeTHF concentration was associated with a 0.50- $\mu$ mol/L decrease in Hcy concentration (95% CI: -0.69, -0.31;  $P$  < 0.001) among all participants. Consistently, when 5-MeTHF concentration was assessed as quartiles, the adjusted  $\beta$ s for participants in quartiles 2, 3 and 4 were -2.18 (95% CI: -3.32, -1.03;  $P$  < 0.001), -2.51 (95% CI: -3.71, -1.31;  $P$  < 0.001) and -3.62 (95% CI: -4.87, -2.38;  $P$  < 0.001), respectively, when compared with those in quartile 1 ( $P$  for trend < 0.001) (Table 2).

Similarly, a significant, negative association was also found in genotype CT and TT participants, however, it was slightly not significant in genotype CC participants. A 1-ng/mL increase in 5-MeTHF concentration was associated with a 0.14- $\mu$ mol/L decrease (95% CI: -0.30, 0.02;  $P$  = 0.087), a 0.20- $\mu$ mol/L decrease (95% CI: -0.35, -0.05;  $P$  = 0.011) and a 1.19- $\mu$ mol/L decrease (95% CI: -1.77, -0.62;  $P$  < 0.001) in Hcy concentration among CC, CT and TT genotype participants, respectively (Table 2). Moreover, the results showed that among participants whose serum 5-MeTHF was  $\leq$  10 ng/mL, the decline in trend in genotype TT participants was stronger than that in genotype CC and genotype CT participants, and there was no significant difference in the decline in trend between genotype CC and genotype CT participants. However, there were no significant differences in the decline in trend between genotype CC, genotype CT and genotype TT participants, whose serum 5-MeTHF concentrations were over 10ng/mL (**Supplemental Table 5**).

Decrements in Hcy among CC genotype participants in quartile 2 ( $P$  = 0.662), quartile 3 ( $P$  = 0.353) and quartile 4 ( $P$  = 0.070) were not significant compared with quartile 1 when 5-MeTHF was assessed as quartiles. While a declining trend existed, this trend was not significant ( $P$  for trend = 0.061). Genotype CT participants showed a significant decrement in Hcy in quartile 4 ( $P$  = 0.013), but in genotype TT

participants, when compared with quartile 1, all quartiles (all of the  $P$  values were  $\leq 0.001$ ) and the decline in trend were of statistical significance ( $P$  for trend  $< 0.001$ ) (Table 2).

Considering the potential heterogeneity between participants with and without outcomes (incident stroke, cancer or all-cause mortality), we performed a sensitivity analysis on these two sub-groups respectively. The overall association was consistent with the above results regardless of the subgroup (**Supplemental Table 6, Supplemental Table 7**).

There were no similar results found among the participants whose 5-MeTHF concentration was over 10 ng/mL, either in all participants or stratified by MTHFR C677T (**Supplemental Table 4**).

### 3.3 Modification of MTHFR C677T on the association between 5-MeTHF and Hcy

Stratified analyses were performed to assess the association between serum 5-MeTHF ( $\leq 10$  ng/mL, as a continuous variable) and Hcy (**Supplemental Table 8**) in various subgroups including MTHFR C677T. A significantly stronger negative association between serum 5-MeTHF and Hcy was observed in genotype TT participants (per increment,  $\beta$ : -1.19; 95% CI: -1.77, -0.62;  $P < 0.001$ ) than in genotype CC participants (per increment,  $\beta$ : -0.14; 95% CI: -0.30, 0.02;  $P = 0.087$ ) and genotype CT participants (per increment,  $\beta$ : -0.20; 95% CI: -0.35, -0.05;  $P = 0.011$ ). However, there was no significant difference between genotype CC and genotype CT participants (**Supplemental Table 5**). Further, in participants with lower vitamin B12  $\leq 381.4$  pg/mL (per increment,  $\beta$ : -0.75; 95% CI: -1.08, -0.41;  $P < 0.001$ ) a significantly stronger negative association was observed than in those with vitamin B12  $> 381.4$  pg/mL (per increment,  $\beta$ : -0.27; 95% CI: -0.46, -0.07;  $P = 0.007$ ;  $P$  for interaction = 0.007).

None of the other variables, including age, SBP, eGFR, vitamin D3 and fasting glucose over the baseline period showed significant effect modification on the association between serum 5-MeTHF and Hcy ( $P$  for interaction  $> 0.05$  for all of these stratified variables).

### 3.4 Interaction effect analysis of 5-MeTHF and MTHFR C677T on Hcy concentration

Participants whose 5-MeTHF concentration was 10 ng/mL, were quartered according to their 5-MeTHF concentration (i.e., Q1, 2.7 ng/mL; Q2, 2.7 –  $< 4.4$  ng/mL; Q3, 4.4 –  $< 6.4$  ng/mL; Q4,  $\geq 6.4$  ng/mL) and were stratified by MTHFR C677T. Moreover, genotype CC participants in quartile 1 were set as reference. Genotype TT participants in Q1 ~ Q4 (all of the adjusted  $P$  values were  $< 0.05$ ) showed significant positive coefficients. In particular, when comparing Q4 in genotype TT participants with Q1 in genotype CC participants (reference), the coefficient was 3.46 (95% CI: 1.17, 5.75;  $P = 0.003$ ). However, there were no significant differences in Q2 ~ Q4 among genotype CC participants and Q1 ~ Q4 among genotype CT participants when compared with Q1 among genotype CC participants (all of the adjusted  $P$  values were  $> 0.05$ ), and the  $P$  value for the trend test was  $< 0.001$  (**Table 3**).

**Table 3. Interaction effect between serum 5-MeTHF ( $\leq 10$ ng/mL) concentration and MTHFR C677T on Hcy concentration**

Subgroups (5-MeTHF ng/mL)	N	Crude Model		Adjusted Model	
		(95% CI)	P Value	(95% CI)	P Value
<b>Genotype CC</b>					
Q1 (< 2.7)	115	<i>Ref</i>	<i>Ref</i>		
Q2 (2.7 - < 4.4)	127	-0.74 (-3.10, 1.61)	0.536	0.35 (-1.79, 2.51)	0.745
Q3 (4.4 - < 6.4)	119	-1.17 (-3.57, 1.22)	0.337	-0.04 (-2.25, 2.17)	0.973
Q4 ( $\geq 6.4$ )	124	-1.12 (-3.49, 1.25)	0.355	-0.01 (-2.23, 2.22)	0.996
<b>Genotype CT</b>					
Q1 (< 2.7)	213	1.53 (-0.59, 3.65)	0.157	1.21 (-0.72, 3.15)	0.217
Q2 (2.7 - < 4.4)	204	0.55 (-1.59, 2.68)	0.615	0.54 (-1.41, 2.51)	0.583
Q3 (4.4 - < 6.4)	226	-0.37 (-2.47, 1.73)	0.729	0.52 (-1.44, 2.49)	0.602
Q4 ( $\geq 6.4$ )	226	-1.39 (-3.49, 0.71)	0.195	0.11 (-1.88, 2.11)	0.910
<b>Genotype TT</b>					
Q1 (< 2.7)	132	15.80 (13.67, 18.14)	< 0.001	14.77 (12.63, 16.92)	< 0.001
Q2 (2.7 - < 4.4)	129	8.16 (5.81, 10.51)	< 0.001	8.00 (5.83, 10.17)	< 0.001
Q3 (4.4 - < 6.4)	114	7.07 (4.65, 9.49)	< 0.001	7.22 (4.94, 9.50)	< 0.001
Q4 ( $\geq 6.4$ )	111	2.60 (0.16, 5.03)	0.037	3.46 (1.17, 5.75)	0.003
<i>P</i> for trend			< 0.001		< 0.001
<i>P</i> for interaction			< 0.001		< 0.001

Adjusted for sex, age, study site, BMI, systolic blood pressure, diastolic blood pressure, estimated glomerular filtration rate, total cholesterol, triglycerides, high-density lipoprotein cholesterol, vitamin B12, vitamin D3, fasting glucose, folate, smoking and drinking at baseline.

## 4. Discussion

In this cross-sectional study derived from the CSPPT, we demonstrated a significant inverse association between serum 5-MeTHF concentration and Hcy concentration among a Chinese hypertensive population, and this association was regulated by MTHFR C677T. Moreover, the inverse association was mainly found in participants whose serum 5-MeTHF was  $\leq 10$  ng/mL.

Former studies have demonstrated the equivalent or better bioavailability of 5-MeTHF in elevating blood concentration of 5-MeTHF and safety compared with folate[15-17], however, the association between 5-MeTHF and Hcy remains to be inconsistent. A recent study conducted in a Japanese pregnant cohort (n = 434) stated a significant, negative association between serum 5-MeTHF and Hcy at each blood sampling period (early pregnancy, late pregnancy, at birth, and cord blood)[10]. Agata et al. recruited 144 participants aged 19-64 years and found no association between plasma 5-MeTHF and Hcy but found a weak association between whole blood 5-MeTHF and Hcy ( $r = -0.18$ ;  $P = 0.043$ )[18]. However, Ji et al. found a significant, negative relationship between whole blood 5-MeTHF and Hcy in healthy participants aged from 20 to 25 years (n = 44;  $r = -0.52$ ;  $P < 0.001$ )[11], and Elizabeth et al. found a significant, negative relationship between rectal mucosal 5-MeTHF and plasma Hcy in bowel cancer individuals (n = 95;  $r = -0.16$ ;  $P = 0.017$ )[12]. Differences in the results between these studies might be attributed to the heterogeneity of the population and the sample size. Moreover, vitamin B12 and vitamin D3, which have been reported as a modifier of methionine synthase reductase (MTR) and a reduced folate carrier, respectively[19, 20], were not taken into account in the analysis either. Our current study focused on a Chinese middle-aged and elderly hypertensive population and the inverse association derived from this study was consistent with former studies, which may indicate that an inverse association generally exists among this population.

Compared with former studies, our study provides two novel insights. First, this was the largest study designed to evaluate the association between serum 5-MeTHF and Hcy, and it identified the turning point of serum 5-MeTHF to be at 10ng/mL, where a significant inverse association between 5-MeTHF and Hcy was shown when serum 5-MeTHF concentration was  $\leq 10$  ng/mL. From the perspective of one-carbon metabolism, 5-MeTHF provides a methyl group and homocysteine is remethylated to methionine in the presence of methionine synthase and further converted to S-adenosine methionine (SAM)[19]. However, when serum 5-MeTHF concentration comes to a certain level, methionine synthase approaches its maximum enzyme activity accumulation, which may account for the inverse association between serum 5-MeTHF and Hcy merely when serum 5-MeTHF was  $\leq 10$  ng/mL. Second, to our knowledge, this was the first study to qualify the determination of MTHFR C677T on the relationship between serum 5-MeTHF and Hcy, and revealed an effect pattern. The initial report by Frosst et al. demonstrated significantly elevated plasma Hcy levels in the homozygous MTHFR C677T mutant[9]. This association was further proven to be presented only in individuals with low folate status[21]. The results derived from our study were similar with these conclusions. When the participants whose serum 5-MeTHF was  $\leq 10$  ng/mL were stratified by MTHFR C677T, it was apparent that serum Hcy concentration in genotype CC participants was not sensitive to the serum 5-MeTHF. By contrast, genotype CT and TT participants showed a significant decline in trend. The possible mechanisms by which genotype TT participants declined more dramatically than genotype CT and CC participants may be due to the decrease in MTHFR enzymatic activity, leading to the accumulation of Hcy[22], while higher levels of Hcy creates more sensitivity to changes in serum 5-MeTHF. Further studies are needed to verify this hypothesis. Previous studies have demonstrated that folate and vitamin B12 status can affect the enzyme activity of MTHFR and methionine synthase, respectively[19, 23]. In our current study, genotype TT participants had relatively low

levels of folate, low vitamin B12 concentrations and higher diastolic blood pressure compared with genotype CC and genotype CT participants, which may partly mask the association between serum 5-MeTHF and Hcy[24, 25]. We observed that vitamin B12 status modified but did not alter this association. We conjecture that although our current study findings suggest that these factors did not distort the relation, they may have partly attenuated or enhanced the decline in trend. Accordingly, our study indicated a dose-response relation of 5-MeTHF with Hcy, and pointed out potential factors that might affect the multidimensional process of 5-MeTHF supplementation.

A few limitations of our study should be addressed. First, our study was a baseline cross-sectional and a secondary analysis of the CSPPT. This study was not included in the original protocol of the trial, nor in the clinical trial registration. Second, the current study did not take the polymorphism of methionine synthase into account. Third, our current study was conducted in hypertensive patients, thus the generalizability of the results to adults without hypertension remains to be examined. Overall, our findings were just hypothesis-generating. All reported results should be further investigated and confirmed in future studies. If further confirmed, our findings may lend further support that maintaining a relatively higher serum 5-MeTHF status may be helpful for the prevention of hyperhomocysteinemia or relative cardiovascular diseases triggered by hyperhomocysteinemia in hypertensive patients regardless of polymorphisms of MTHFR C677T.

## 5. Conclusion

In summary, a non-linear association was found between serum 5-MeTHF and Hcy in Chinese hypertensive participants, however, serum 5-MeTHF was significantly, inversely, and linearly associated with Hcy when serum 5-MeTHF was  $\leq 10$  ng/mL. Moreover, homozygous MTHFR C677T mutant participants significantly differed from those who were wild and heterozygous type.

## 6. Abbreviations

5-MeTHF: 5-tetrahydrofolate; Hcy: homocysteine; MTHFR: methylene tetrahydrofolate reductase; CSPPT: China Stroke Primary Prevention Trial; CKD: chronic kidney disease; IQR: interquartile range; MTR: methionine synthase reductase; SAM: S-adenosine methionine

## 7. Declarations

### Ethics approval and consent to participate

The parent study (the China Stroke Primary Prevention Trial, CSPPT) was approved by the Ethics Committee of the Institute of Biomedicine, Anhui Medical University, Hefei, China (federal-wide assurance number: FWA00001263). All participants provided written, informed consent.

### Consent for publication

All the co-authors are approval for publication.

### **Availability of data and materials**

The datasets used and analyzed during the current study could be available from the corresponding author on reasonable request.

### **Competing interests**

The co-authors declare no competing interests.

### **Funding**

The study was supported by funding from the following: the National Key Research and Development Program of China [2016YFE0205400, 2018ZX09739010, 2018ZX09301034003]; the Science and Technology Program of Guangdong, China [2020B121202010]; the Science and Technology Planning Project of Guangzhou [201707020010]; the Science, Technology and Innovation Committee of Shenzhen, China [GJHS20170314114526143, JS GG20180703155802047]; the Economic, Trade and Information Commission of Shenzhen Municipality, China [20170505161556110, 20170505160926390, 201705051617070]; the National Natural Science Foundation of China [81730019, 81973133, 81960074, 81500233]; the Research Fund Program of Guangdong Provincial Key Laboratory of Renal Failure Research, Clinical Innovation Research Program of Guangzhou Regenerative Medicine and Health Guangdong Laboratory [2018GZR0201003]; Jiangxi Outstanding Person Foundation [20192BCBL23024]; and the Major projects of the Science and Technology Department, Jiangxi, China [20171BAB205008].

### **Author's contributions**

Conceptualization, Yu Cheng, Xianhui Qin and Fangrong Yan; Data curation, Lishun Liu; Formal analysis, Ziyi Zhou, Nan Zhang, Zhuo Wang and Lishun Liu; Funding acquisition, Xianhui Qin; Investigation, Yun Song, Xiangyi Liu, Yong Duan, Xiuwen Liang, Bingjie Hou, Binyan Wang and Genfu Tang; Methodology, Yu Cheng, Ziyi Zhou, Nan Zhang, Xianhui Qin and Fangrong Yan; Project administration, Yu Cheng and Fangrong Yan; Resources, Yong Duan, Genfu Tang, Xianhui Qin and Fangrong Yan; Supervision, Xianhui Qin and Fangrong Yan; Validation, Shuai Liu, Duo Chen, Yiman Yang, Qiongyue Liang and Ya Huo; Writing – original draft, Yu Cheng, Xianhui Qin and Fangrong Yan; Writing – review & editing, Xianhui Qin and Fangrong Yan.

### **Acknowledgements**

We thank the investigators and participants of the osteoporosis cohort study, the parent study, who made this report possible. Xiping Xu, the PI of the osteoporosis cohort study, has full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

### **Conflicts of interest:**

All authors have completed the ICMJE uniform disclosure form and have declared the following:

Dr. Xiping Xu reports grants from the National Key Research and Development Program of China [2016YFE0205400, 2018ZX09739010, 2018ZX09301034003]; the Science and Technology Program of Guangdong, China [2020B121202010]; the Science and Technology Planning Project of Guangzhou, China [201707020010]; the Science, Technology and Innovation Committee of Shenzhen, China [GJHS20170314114526143, JSGG20180703155802047]; and the Economic, Trade and Information Commission of Shenzhen Municipality [20170505161556110, 20170505160926390, 201705051617070].

Dr. Xianhui Qin reports grants from the National Natural Science Foundation of China [81730019, 81973133]; and the Research Fund Program of Guangdong Provincial Key Laboratory of Renal Failure Research, Clinical Innovation Research Program of Guangzhou Regenerative Medicine and Health Guangdong Laboratory [2018GZR0201003].

No other disclosures were reported.

## References


1. Qin X, Huo Y: **H-Type hypertension, stroke and diabetes in China: Opportunities for primary prevention.***J Diabetes* 2016, **8**:38-40.
2. Ganguly P, Alam SF: **Role of homocysteine in the development of cardiovascular disease.***Nutr J* 2015, **14**:6.
3. Malinow MR, Bostom AG, Krauss RM: **Homocyst(e)ine, diet, and cardiovascular diseases: a statement for healthcare professionals from the Nutrition Committee, American Heart Association.***Circulation* 1999, **99**:178-182.
4. Xu X, Qin X, Li Y, Sun D, Wang J, Liang M, Wang B, Huo Y, Hou FF: **Efficacy of Folic Acid Therapy on the Progression of Chronic Kidney Disease: The Renal Substudy of the China Stroke Primary Prevention Trial.***JAMA Intern Med* 2016, **176**:1443-1450.
5. Pfeiffer CM, Sternberg MR, Fazili Z, Yetley EA, Lacher DA, Bailey RL, Johnson CL: **Unmetabolized folic acid is detected in nearly all serum samples from US children, adolescents, and adults.***J Nutr* 2015, **145**:520-531.
6. Sweeney MR, McPartlin J, Weir DG, Daly L, Scott JM: **Postprandial serum folic acid response to multiple doses of folic acid in fortified bread.***Br J Nutr* 2006, **95**:145-151.
7. Troen AM, Mitchell B, Sorensen B, Wener MH, Johnston A, Wood B, Selhub J, McTiernan A, Yasui Y, Oral E, et al: **Unmetabolized folic acid in plasma is associated with reduced natural killer cell cytotoxicity among postmenopausal women.***J Nutr* 2006, **136**:189-194.
8. Matthews RG, Daubner SC: **Modulation of methylenetetrahydrofolate reductase activity by S-adenosylmethionine and by dihydrofolate and its polyglutamate analogues.***Adv Enzyme Regul* 1982, **20**:123-131.



9. Frosst P, Blom H, Milos R, Goyette P, Sheppard CA, Matthews R, Boers G, Den Heijer M, Kluijtmans L, Van Den Heuvel L: **A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase.***Nature genetics* 1995, **10**:111-113.
10. Kubo Y, Fukuoka H, Kawabata T, Shoji K, Mori C, Sakurai K, Nishikawa M, Ohkubo T, Oshida K, Yanagisawa N, Yamashiro Y: **Distribution of 5-Methyltetrahydrofolate and Folic Acid Levels in Maternal and Cord Blood Serum: Longitudinal Evaluation of Japanese Pregnant Women.***Nutrients* 2020, **12**.
11. Ji Y, Luo H, Li H, Lin Z, Luo W: **Determination of plasma homocysteine with a UHPLC-MS/MS method: Application to analyze the correlation between plasma homocysteine and whole blood 5-methyltetrahydrofolate in healthy volunteers.***Biomed Chromatogr* 2020, **34**:e4845.
12. Williams EA, Welfare M, Spiers A, Hill MH, Bal W, Gibney ER, Duckworth Y, Powers HJ, Mathers JC: **Systemic folate status, rectal mucosal folate concentration and dietary intake in patients at differential risk of bowel cancer (The FAB2 Study).***Eur J Nutr* 2013, **52**:1801-1810.
13. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J: **Global burden of hypertension: analysis of worldwide data.***The lancet* 2005, **365**:217-223.
14. Huo Y, Li J, Qin X, Huang Y, Wang X, Gottesman RF, Tang G, Wang B, Chen D, He M, et al: **Efficacy of folic acid therapy in primary prevention of stroke among adults with hypertension in China: the CSPPT randomized clinical trial.***Jama* 2015, **313**:1325-1335.
15. Lamers Y, Prinz-Langenohl R, Brämswig S, Pietrzik K: **Red blood cell folate concentrations increase more after supplementation with [6S]-5-methyltetrahydrofolate than with folic acid in women of childbearing age.***Am J Clin Nutr* 2006, **84**:156-161.
16. Niederberger KE, Dahms I, Broschard TH, Boehni R, Moser R: **Safety evaluation of calcium L-methylfolate.***Toxicol Rep* 2019, **6**:1018-1030.
17. Zajecka JM, Fava M, Shelton RC, Barrentine LW, Young P, Papakostas GI: **Long-term efficacy, safety, and tolerability of L-methylfolate calcium 15 mg as adjunctive therapy with selective serotonin reuptake inhibitors: a 12-month, open-label study following a placebo-controlled acute study.***J Clin Psychiatry* 2016, **77**:654-660.
18. Sobczyńska-Malefora A, Harrington DJ, Voong K, Shearer MJ: **Plasma and red cell reference intervals of 5-methyltetrahydrofolate of healthy adults in whom biochemical functional deficiencies of folate and vitamin B 12 had been excluded.***Adv Hematol* 2014, **2014**:465623.
19. Obeid R, Herrmann W: **The emerging role of unmetabolized folic acid in human diseases: myth or reality?***Curr Drug Metab* 2012, **13**:1184-1195.
20. Alam C, Hoque MT, Finnell RH, Goldman ID, Bendayan R: **Regulation of Reduced Folate Carrier (RFC) by Vitamin D Receptor at the Blood-Brain Barrier.***Mol Pharm* 2017, **14**:3848-3858.
21. Papoutsakis C, Yiannakouris N, Manios Y, Papaconstantinou E, Magkos F, Schulpis KH, Zampelas A, Matalas AL: **Plasma homocysteine concentrations in Greek children are influenced by an interaction between the methylenetetrahydrofolate reductase C677T genotype and folate status.***J Nutr* 2005, **135**:383-388.

22. Herrmann W, Obeid R, Schorr H, Zarzour W, Geisel J: **Homocysteine, methylenetetrahydrofolate reductase C677T polymorphism and the B-vitamins: a facet of nature-nurture interplay.***Clin Chem Lab Med* 2003, **41**:547-553.
23. Huang X, Qin X, Yang W, Liu L, Jiang C, Zhang X, Jiang S, Bao H, Su H, Li P, et al: **MTHFR Gene and Serum Folate Interaction on Serum Homocysteine Lowering: Prospect for Precision Folic Acid Treatment.***Arterioscler Thromb Vasc Biol* 2018, **38**:679-685.
24. Vanjani MV, Phulari RGS, Rathore R: **Evaluation of relationship between serum homocysteine and Vitamin B12 levels in oral submucous fibrosis patients using chemiluminescence immunoassay.***J Oral Maxillofac Pathol* 2019, **23**:363-368.
25. Wu H, Wang B, Ban Q, Chen L, Yan D, Yu Y, Song Y, Liu C, Cao J, Zhang J, et al: **Association of total homocysteine with blood pressure in a general population of Chinese adults: a cross-sectional study in Jiangsu province, China.***BMJ Open* 2018, **8**:e021103.

## Figures



**Figure 1**

Association of Hcy levels and 5-MeTHF levels among all participants (A) and stratified by MTHFR C677T (B). Panel A was adjusted for sex, age, study site, MTHFR C677T, BMI, systolic blood pressure, diastolic blood pressure, estimated glomerular filtration rate, total cholesterol, triglycerides, high-density lipoprotein cholesterol, vitamin B12, vitamin D3, fasting glucose, folate, smoking and drinking at baseline. Panel B was adjusted for the variables in panel A but removed MTHFR C677T.

## Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [Suplmentalfigure.docx](#)
- [Suplmentaltables.docx](#)